Atlas Trials

Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer

Clinical trial NCT06700603 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06700603
Sponsor
Rui-hua Xu, MD, PhD
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2024-11-20
Primary completion
2025-12-31
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.